As of May 23, 2025, Willow Biosciences Inc has a Discounted Cash Flow (DCF) derived fair value of $0.00 per share. With the current market price at $0.04, this represents a potential upside of -20979043.7%.
| Key Metrics | Value |
|---|---|
| DCF Fair Value (5-year) | $0.00 |
| DCF Fair Value (10-year) | $0.00 |
| Potential Upside (5-year) | -712692.3% |
| Potential Upside (10-year) | -20979043.7% |
| Discount Rate (WACC) | 8.3% - 10.7% |
Revenue is projected to grow from $5 million in 12-2024 to $14192 million by 12-2034, representing a compound annual growth rate of approximately 121.5%.
| Fiscal Year | Revenue (USD millions) | Growth |
|---|---|---|
| 12-2024 | 5 | 298% |
| 12-2025 | 5 | 6% |
| 12-2026 | 15 | 211% |
| 12-2027 | 48 | 211% |
| 12-2028 | 129 | 171% |
| 12-2029 | 329 | 154% |
| 12-2030 | 785 | 139% |
| 12-2031 | 1751 | 123% |
| 12-2032 | 3729 | 113% |
| 12-2033 | 7478 | 101% |
| 12-2034 | 14192 | 90% |
Net profit margin is expected to improve from -133% in 12-2024 to -133% by 12-2034, driven by operational efficiency and economies of scale.
| Fiscal Year | Net Profit (USD millions) | Profit Margin |
|---|---|---|
| 12-2024 | (6) | -133% |
| 12-2025 | (7) | -133% |
| 12-2026 | (20) | -133% |
| 12-2027 | (63) | -133% |
| 12-2028 | (172) | -133% |
| 12-2029 | (436) | -133% |
| 12-2030 | (1,042) | -133% |
| 12-2031 | (2,323) | -133% |
| 12-2032 | (4,946) | -133% |
| 12-2033 | (9,919) | -133% |
| 12-2034 | (18,824) | -133% |
with a 5-year average of $1 million. Projected CapEx is expected to maintain at approximately 2300% of revenue.
Depreciation is based on an average useful life of 5 years for capital assets.
| Fiscal Year | D&A (USD millions) |
|---|---|
| 12-2025 | 23 |
| 12-2026 | 93 |
| 12-2027 | 313 |
| 12-2028 | 908 |
| 12-2029 | 2419 |
| 12-2030 | 6008 |
Net working capital is expected to increase gradually, with projected changes affecting free cash flow.
| Components | Average Days |
|---|---|
| Days Receivables | 60 |
| Days Inventory | 0 |
| Days Payables | 0 |
| Fiscal Year | EBITDA | Tax | CapEx | Change in NWC | FCF |
|---|---|---|---|---|---|
| 2025 | 17 | (0) | 113 | 1 | (97) |
| 2026 | 74 | (0) | 352 | 1 | (280) |
| 2027 | 251 | (0) | 1097 | 3 | (848) |
| 2028 | 741 | (0) | 2977 | 11 | (2,247) |
| 2029 | 1997 | (0) | 7556 | 19 | (5,578) |
| Valuation Method | Fair Price (USD) | Potential Upside |
|---|---|---|
| 5-Year DCF (Growth) | 0.00 | -712692.3% |
| 10-Year DCF (Growth) | 0.00 | -20979043.7% |
| 5-Year DCF (EBITDA) | 0.00 | -100.0% |
| 10-Year DCF (EBITDA) | 0.00 | -100.0% |
Is Willow Biosciences Inc (WLLW.TO) a buy or a sell? Willow Biosciences Inc is definitely a sell. Based on our DCF analysis, Willow Biosciences Inc (WLLW.TO) appears to be overvalued with upside potential of -20979043.7%. The company's strong projected growth in revenue and profitability, coupled with consistent capital expenditure, supports our positive outlook on its intrinsic value.
Key investment drivers include:
Investors should consider reducing exposure at the current market price of $0.04.